Success Metrics

Clinical Success Rate
70.8%

Based on 34 completed trials

Completion Rate
71%(34/48)
Active Trials
17(22%)
Results Posted
56%(19 trials)
Terminated
14(18%)

Phase Distribution

Ph phase_1
15
19%
Ph phase_2
52
68%
Ph phase_3
9
12%

Phase Distribution

15

Early Stage

52

Mid Stage

9

Late Stage

Phase Distribution76 total trials
Phase 1Safety & dosage
15(19.7%)
Phase 2Efficacy & side effects
52(68.4%)
Phase 3Large-scale testing
9(11.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.0%

34 of 54 finished

Non-Completion Rate

37.0%

20 ended early

Currently Active

17

trials recruiting

Total Trials

77

all time

Status Distribution
Active(18)
Completed(34)
Terminated(20)
Other(5)

Detailed Status

Completed34
Terminated14
Active, not recruiting9
Recruiting8
Withdrawn6
unknown5

Development Timeline

Analytics

Development Status

Total Trials
77
Active
17
Success Rate
70.8%
Most Advanced
Phase 3

Trials by Phase

Phase 115 (19.7%)
Phase 252 (68.4%)
Phase 39 (11.8%)

Trials by Status

active_not_recruiting912%
completed3444%
terminated1418%
unknown56%
withdrawn68%
not_yet_recruiting11%
recruiting810%

Recent Activity

Clinical Trials (77)

Showing 20 of 77 trialsScroll for more
NCT03419234Phase 2

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Active Not Recruiting
NCT06632977Phase 2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Recruiting
NCT07213674Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Recruiting
NCT03048942Phase 2

Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Completed
NCT05818683Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Recruiting
NCT07611110Phase 3

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Recruiting
NCT03263650Phase 2

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Completed
NCT04592237Phase 2

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active Not Recruiting
NCT06085729Phase 1

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Recruiting
NCT06353386Phase 1

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Recruiting
NCT03934840Phase 2

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Completed
NCT06691984Phase 3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Active Not Recruiting
NCT02115165Phase 2

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Completed
NCT02703623Phase 2

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Active Not Recruiting
NCT02522715Phase 1

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Active Not Recruiting
NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed
NCT06470243Phase 3

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Recruiting
NCT02985957Phase 2

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Completed
NCT04709276Phase 2

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Active Not Recruiting
NCT01952223Phase 3

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
77